The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
986
October 25, 1996
View Complete Issue         Table of Contents 2019 
Lispro, A Rapid-Onset Insulin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lispro, A Rapid-Onset Insulin
October 25, 1996 (Issue: 986)
Lispro insulin (Humalog - Lilly), a synthetic insulin analog, has been approved for marketing by the US Food and Drug Administration. Prepared by recombinant DNA methods using E. coli, lispro differs from human insulin in having lysine and proline...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lispro, A Rapid-Onset Insulin
Article code: 986c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.